HCA
KROS icon

Hyperion Capital Advisors’s Keros Therapeutics KROS Stock Holding History

Hyperion Capital Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,042
Closed -$220K – 61
2022
Q1 		$220K Hold
4,042
– – 0.08% 53
2021
Q4 		$236K Buy
+4,042
New +$202K 0.05% 47

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Hyperion Capital Advisors's KROS Position: Q2 2022 in Review

Hyperion Capital Advisors sold out of Keros Therapeutics (KROS) in Q2 2022, closing a stake of 4,042 shares — an estimated $220K sold.

Hyperion Capital Advisors first reported a position in KROS in Q4 2021 and held it in 2 quarters. The position peaked at $236K in Q4 2021. 104 funds tracked by Wall St. Rank hold KROS as of Q2 2022.

  • Hyperion Capital Advisors reported no remaining Keros Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Hyperion Capital Advisors sold 4,042 Keros Therapeutics shares in Q2 2022, an estimated $220K.
  • Hyperion Capital Advisors first reported a position in Keros Therapeutics in Q4 2021 and held it in 2 quarters.
  • Hyperion Capital Advisors's Keros Therapeutics position peaked at $236K in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2022.

Based on Hyperion Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.